Elaina M. Gartner - Concepedia

Author

Elaina M. Gartner

The Barbara Ann Karmanos Cancer Institute

Also Known As

E Gartner, E Gärtner, E. Gartner, E. Gärtner, E. M. Gartner, E.M. Gartner, Elaina Gartner, Elaina M Gartner, Elaina M. Gartner

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

The Barbara Ann Karmanos Cancer Institute Seagen (United States)Wayne State University Astellas Pharma (United States)Memorial Sloan Kettering Cancer Center

About

Elaina M. Gartner is an author at The Barbara Ann Karmanos Cancer Institute specializing in cancer therapeutics, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.1K
2	Pathology	5	5	161
3	Health Sciences	4	4	655
4	Immunology	4	4	104
5	Cell Biology	2	2	55

Elaina M. Gartner

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Journal of Clinical Oncology	2019	598
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, Journal of Clinical Oncology	2020	311
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells Robert H. Vonderheide, Patricia LoRusso, Magi Khalil, Clinical Cancer Research	2010	301
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma Nizar M. Tannir, Andres Forero‐Torres, Radhakrishnan Ramchandren, Investigational New Drugs Lymphoid NeoplasiaUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2014	126
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer Michael Clemens, Oleg Gladkov, Elaina M. Gartner, Breast Cancer Research and Treatment	2014	78
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma Shunji Takahashi, Motohide Uemura, Tomokazu Kimura, Investigational New Drugs	2019	77
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma Tycel Phillips, Paul M. Barr, Steven I. Park, Investigational New Drugs	2018	76
A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma Sumanta K. Pal, Andres Forero‐Torres, John A. Thompson, Cancer	2019	64
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer Elaina M. Gartner, Paula Silverman, Michael S. Simon, Breast Cancer Research and Treatment Breast OncologyMedicinePharmacologyPhase Ii StudyBreast Cancer	2011	63

Page 1